// App-Quantinova.ai

1653 : The HB22.7 Anti-CD22 Monoclonal Antibody Is an Effective Platform for CD22-Targeted Antibody Drug Conjugates for Treatment of Lymphoma and Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Jason Kato

Principal Investigators

  • Robert -Donnell

  • Joseph Tuscano

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Translocator protein

  • Apparent diffusion coefficient

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved